Previous 10 | Next 10 |
2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...
2023-07-05 17:35:55 ET VBI Vaccines ( NASDAQ: VBIV ) is down ~3% in after-hours trading Wednesday after it announced an underwritten public offering and a registered direct offering of common shares and warrants. Raymond James is the sole book-runner. VBI ( ...
VBI Vaccines Inc. ( NASDAQ: VBIV ) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered dire...
Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region VBI will receive gross proceeds of $15 million in upfront payments, subject to near-term milestone achievements, including an equity investment of appr...
2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...
2023-07-03 08:22:42 ET Baudax Bio ( BXRX ) -13% . VBI Vaccines ( VBIV ) -12% . Addentax Group ( ATXG ) -10% . AstraZeneca PLC ( AZN ) -7% . TOP Financial Group Limited ( TOP ) -4% . For further details see: AZN and VBIV amo...
2023-07-02 08:29:00 ET 3 Top Facts to Consider When Investing in Penny Stocks The allure of penny stocks, typically defined as stocks trading for less than $5 per share, has drawn countless investors to try their hand at uncovering the next big success story. They offer a tempting propo...
PreHevbri ® is the only approved 3-antigen hepatitis B vaccine for adults in the U.K. Product to be launched via marketing and distribution partner, Valneva VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful p...
2023-06-07 13:57:29 ET VBI Vaccines ( NASDAQ: VBIV ) added ~9% on Wednesday, albeit on below-average volumes, after the biotech announced an upcoming presentation on its Hepatitis B vaccine PreHevbrio at a European medical event later this month. The Cambridge, Massachusetts...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-anti...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...